Navigate 340B Drug Pricing Program Manufacturer Restrictions with Strategic Precision

Manufacturer restrictions are limitations that drug companies have implemented to control how 340B covered entities can use 340B discounted drugs at contract pharmacies. These restrictions may limit which contract pharmacies can dispense 340B drugs, require specific data reporting, or restrict the types of patients who can receive discounted 340B pricing. Drug manufacturers implemented these restrictions to reduce their financial exposure under the federal 340B drug discount program.

Manufacturer restrictions can significantly reduce your ability to use 340B revenue and capture maximum savings from the drug discount program. When drug companies restrict access to contract pharmacies, covered entities may lose the ability to purchase 340B drugs at discounted pricing for certain patient populations. This forces organizations to choose between maintaining patient access through their pharmacy network or preserving 340B discount savings, directly impacting how 340B revenue is used to support community health programs.

Manufacturer restrictions can significantly reduce your ability to use 340B revenue and capture maximum savings from the drug discount program. When drug companies restrict access to contract pharmacies, covered entities may lose the ability to purchase 340B drugs at discounted pricing for certain patient populations. This forces organizations to choose between maintaining patient access through their pharmacy network or preserving 340B discount savings, directly impacting how 340B revenue is used to support community health programs.

The Health Resources and Services Administration (HRSA) provides oversight of the 340B program and has issued guidance regarding manufacturer restrictions, though enforcement remains limited. HRSA has stated that manufacturers cannot impose restrictions that are inconsistent with the 340B statute under Section 340B of the Public Health Service Act. However, the ongoing legal disputes between drug companies and the Department of Health and Human Services create uncertainty about which restrictions are permissible under current program requirements.

Yes, covered entities can continue to participate in the 340B drug pricing program despite manufacturer restrictions. However, organizations must carefully evaluate which restrictions apply to their operations and develop strategies to maintain compliance while preserving program benefits. The drug pricing program was created to help safety net providers stretch federal resources, and restrictions should not prevent eligible organizations from participating in the program, though they may limit certain operational approaches.

Manufacturer restrictions often stem from concerns about duplicate discounts between the 340B program and the Medicaid drug rebate program. The 340B statute requires that covered entities not seek reimbursement from state Medicaid programs for drugs purchased at 340B prices to prevent duplicate discounts. Drug manufacturers argue that some contract pharmacy arrangements make it difficult to track whether drugs purchased under the 340B drug discount program are being properly excluded from Medicaid rebate calculations.

When manufacturer restrictions are in place, covered entities must carefully distinguish between 340B and non-340B drugs to ensure proper handling and billing. Drugs outside the 340B program can be dispensed normally through contract pharmacies, while 340B discounted drugs may be subject to specific restrictions. Organizations must implement systems to track which drugs were purchased at the 340B price versus wholesale acquisition cost to maintain compliance and preserve their ability to use 340B benefits.

Organizations can protect the 340B program by developing comprehensive restriction management strategies that balance compliance requirements with operational needs. This includes conducting regular reviews of the 340B program to identify applicable restrictions, implementing robust tracking systems for 340B and non-340B drug dispensing, and working with contract pharmacies to ensure proper handling of discounted 340B drugs. The goal is to strengthen the 340B program within your organization while adapting to the evolving regulatory landscape.